$9.61

0.46 (5.03%)

10/10/2008 4:01 PM

Caraco Pharmaceutical Laboratories Ltd. (CPD)

CAPS Rating:

The Company is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to the wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CPD

Add Stock to Watchlist

What the Community Thinks

Total Members

145 Outperforms

7 Underperforms

All-Stars

35 Outperforms

2 Underperforms

Members bullish on CPD are also bullish on:

Members bearish on CPD are also bearish on:

Ticker Tags

Micro Cap (4824), Small Cap (1922), Drugs - Generic (14)
Suggest a tag

Caraco Pharmaceutical Laboratories Ltd. At A Glance

Current Price:	$9.61
Last Trade Time:	10/10/2008 4:01 PM
Open:	$8.80
Previous Close:	$9.15
Daily Range:	$7.35 - $9.61
52-Week Range:	$8.53 - $18.70
Volume:	139,213
Market Cap:	$442.63M
P/E Ratio:	11.33
Compare Our Special Broker Offers!

Stock Trends

CPD VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for CPD

Sector Glance: Generic Drug Makers
12/18/2007 4:42:00 PM - AP
Sector Glance: Generic Drug Makers
12/4/2007 4:32:00 PM - AP
Sector Glance: Generic Drugmakers
12/3/2007 5:09:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

2 Caraco Pharmaceutical Laboratories Ltd. (CPD)

Avatar Gtrinvestor (99.99) Submitted: 9/18/08 1:37 PM

Re-up on this company due to its drop in price over the past several months. Here is a small part of my original pitch (more to follow later):

Here is a great, but lengthy, article on CPD. I still hold this one in my personal portfolio, and plan on doing so for quite a while.

More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 26 : 1 2 3 4 5 Next »

Recs 0 (CPD) aracer (86.92) Submitted: 10/06/08 2:16 PM : Start Price: $10.30 CPD Score: 6.35 good potential in generics at a great entry for a long hold Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CPD) QuickBen (99.76) Submitted: 10/01/08 1:58 AM : Start Price: $12.55 CPD Score: -0.20 Great PE & growth long hold Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CPD) DollarDoomProfit (< 20) Submitted: 9/29/08 1:10 PM : Start Price: $13.45 CPD Score: -4.66 Undervalued generic drug company, which should benefit under new US President. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CPD) stockblog (71.76) Submitted: 9/28/08 8:10 PM : Start Price: $13.35 CPD Score: -2.27 The generic drug industry is rapidly consolidating amidst a flurry of recent M&A activity -- including the following buyout offers: Industry leader Teva Pharma (TEVA): buyout bids for Barr (BRL) ($7.5B) & Bentley Pharma (BNT) ($350M) Sanofi-Aventis (SNY): a $2B bid for Czech-based Zentiva (which has been rejected) Daiichi-Sankyo (Tokyo: 4568): a $4.6B bid for India-based Ranbaxy (500359) Fresenius Medical (FMS): buyot of generic injectable firm APP Pharma (APPX) valued at up to $4.6B India-based Sun Pharma (524715): offer to buy its remaining stake in Taro Pharma (TAROF) Existing benchmark funds for my Global Generic Drug Index include the pharmaceutical ETFs which contain a mix of biotechs, brand pharma, and generic pharma companies -- including the Pharma HOLDRs (PPH), PowerShares Dynamic Pharma (PJP), iShares Dow Jones US Pharma (IHE), and the S&P Pharma SPDR (XPH). As a pure play index and ETF idea, the global generic drug industry has outpaced all of its drug ETF benchmarks over the past year thanks to widespread M&A, a large number of small/mid-caps, and upcoming key patent expirations for blockbuster brand drugs. Key patents of multi-billion dollar brand drugs are set to expire within the next few years, including Risperdal and Fosamax in 2008, Prevacid and Topamax in 2009, Lipitor and Effexor XR in 2010, Plavix and Actos in 2011, Singulair and Seroquel in 2012. According to IMS Health statistics, generic medications accounted for 63% of all medications dispensed in the United States in 2006, representing a growth rate of over 22% for unbranded generic drugs. Finally, Momenta Pharma (MNTA) is included in my index as a leader in biogenerics. Momenta has surged nearly four-fold since the rejection late last year on word that the FDA is not requiring additional clinical trials for the generic form of Lovenox, with US sales of $750M in 2007 for Sanofi-Aventis. Momenta also recently filed a patent challenge to produce a generic form of the multiple sclerosis drug Copaxone, which is made by Teva. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CPD) redfox18 (25.59) Submitted: 9/25/08 7:28 AM : Start Price: $13.47 CPD Score: -3.13 following gtrinvestor Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 26 : 1 2 3 4 5 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.